At the United European Gastroenterology Week 2019, held in Barcelona, Spain, earlier this year, a research team from the Netherlands reported on the prevalence of patients with inflammatory bowel disease (IBD) switching back to the reference infliximab after a previous switch to biosimilar CT-P13, and found that switching back appeared to be effective in patients with IBD.
Among the reasons documented for some patients discontinuing biosimilar infliximab after switching from the reference product are subjective loss of response and adverse events.
At the United European Gastroenterology Week 2019, held in Barcelona, Spain, earlier this year, a research team from the Netherlands reported on the prevalence of patients with inflammatory bowel disease (IBD) switching back to the reference infliximab after a previous switch to biosimilar CT-P13, and found that switching back appeared to be effective in patients with IBD.
In the retrospective, observation, multicenter cohort study, data from patients with IBD who had switched to CT-P13 and had at least 52 weeks of follow-up were eligible for inclusion. In total, 254 patients were switched, 165 of whom had Crohn disease (CD), 52 of whom had ulcerative colitis (UC), and 2 of whom had unclassified IBD.
In total, 35 patients switched back to the originator drug during the follow-up period. Those who made the switch back were more often female than those who remained on the biosimilar. In total, 91.4% of those who switched back did so because of newly reported side effects. Only 3 (8.6%) switched back due to loss of response.
The side effects most commonly reported were skin reactions (37.1%), increased IBD-related symptoms (37.1%), and fatigue (25.7%). Three patients had calprotectin-objectified loss of response.
In 75% of the patients who reported new side effects and in 100% of the patients with loss of response, switching back to the reference product had the desired effect of improving the side effects or regaining response.
The authors concluded that, for those who experience side effects or a loss of response after a switch to the biosimilar product, a switch back may be justified, and appears to have been effective in this group of patients with IBD.
Reference
Mahmmod S, Schultheiss JPD, Mahmmod N, Tan AC, Dijkstra G, Fidder HH. Reverse switching to originator infliximab may be considered in patients with inflammatory bowel diseases experiencing new side effects or loss of response after switching to a CT-P13 biosimilar. Presented at: United European Gastroenterology Week 2019; October 29-23, 2019; Barcelona, Spain.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.